VIATRIS INC. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax
VIATRIS INC. (VTRS) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax · last filed 2026-08-06
- VIATRIS INC. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for the quarter ending 2026-06-30 was $2.70M.
- VIATRIS INC. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for the quarter ending 2026-03-31 was $1.50M, a 650.00% increase year-over-year.
- VIATRIS INC. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for the quarter ending 2025-12-31 was -$31.50M, a 408.82% decline year-over-year.
- VIATRIS INC. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for the quarter ending 2025-09-30 was $3.90M.
- VIATRIS INC. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2025 was -$27.90M, a 235.44% decline from fiscal 2024.
- VIATRIS INC. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2024 was $20.60M, a 10.16% increase from fiscal 2023.
- VIATRIS INC. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2023 was $18.70M.
- VIATRIS INC. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2022 was -$279.10M.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-06 | $4.20M 10-Q · filed 2026-08-06 | -$27.30M derived: sum of 3 quarters · filed 2026-08-06 | -$23.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-07 | -$30.00M derived: sum of 2 quarters · filed 2026-05-07 | -$26.10M derived: sum of 3 quarters · filed 2026-05-07 | -$26.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$31.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$27.60M derived: sum of 2 quarters · filed 2026-02-26 | -$28.10M derived: sum of 3 quarters · filed 2026-08-06 | -$27.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.90M 10-Q · filed 2025-11-06 | $3.40M derived: sum of 2 quarters · filed 2026-08-06 | $3.60M 10-Q · filed 2025-11-06 | $13.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$500.00K 10-Q · filed 2026-08-06 | -$300.00K 10-Q · filed 2026-08-06 | $9.90M derived: sum of 3 quarters · filed 2026-08-06 | $8.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-07 | $10.40M derived: sum of 2 quarters · filed 2026-05-07 | $9.00M derived: sum of 3 quarters · filed 2026-05-07 | $14.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.80M derived: sum of 2 quarters · filed 2026-02-26 | $14.40M derived: sum of 3 quarters · filed 2026-02-26 | $20.60M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.40M 10-Q · filed 2025-11-06 | $4.20M derived: sum of 2 quarters · filed 2025-11-06 | $10.40M 10-Q · filed 2025-11-06 | $18.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $5.60M 10-Q · filed 2025-08-07 | $11.80M 10-Q · filed 2025-08-07 | $20.10M derived: sum of 3 quarters · filed 2026-02-26 | $25.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $6.20M 10-Q · filed 2025-05-08 | $14.50M derived: sum of 2 quarters · filed 2026-02-26 | $19.40M derived: sum of 3 quarters · filed 2026-02-26 | $26.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.20M derived: sum of 2 quarters · filed 2026-02-26 | $20.00M derived: sum of 3 quarters · filed 2026-02-26 | $18.70M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.90M 10-Q · filed 2024-11-07 | $11.70M derived: sum of 2 quarters · filed 2024-11-07 | $10.40M 10-Q · filed 2024-11-07 | -$272.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $6.80M 10-Q · filed 2024-08-08 | $5.50M 10-Q · filed 2024-08-08 | -$276.90M derived: sum of 3 quarters · filed 2025-02-27 | -$275.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$1.30M 10-Q · filed 2024-05-09 | -$283.70M derived: sum of 2 quarters · filed 2025-02-27 | -$282.50M derived: sum of 3 quarters · filed 2025-02-27 | -$283.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$282.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$281.20M derived: sum of 2 quarters · filed 2025-02-27 | -$281.70M derived: sum of 3 quarters · filed 2025-02-27 | -$279.10M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.20M 10-Q · filed 2023-11-08 | $700.00K derived: sum of 2 quarters · filed 2023-11-08 | $3.30M 10-Q · filed 2023-11-08 | $3.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$500.00K 10-Q · filed 2023-08-07 | $2.10M 10-Q · filed 2023-08-07 | $2.30M derived: sum of 3 quarters · filed 2024-02-28 | $1.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.60M 10-Q · filed 2023-05-08 | $2.80M derived: sum of 2 quarters · filed 2024-02-28 | $2.00M derived: sum of 3 quarters · filed 2024-02-28 | -$70.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$600.00K derived: sum of 2 quarters · filed 2024-02-28 | -$73.10M derived: sum of 3 quarters · filed 2024-02-28 | -$73.90M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$800.00K 10-Q · filed 2022-11-07 | -$73.30M derived: sum of 2 quarters · filed 2022-11-07 | -$74.10M 10-Q · filed 2022-11-07 | -$56.70M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$72.50M 10-Q · filed 2022-08-08 | -$73.30M 10-Q · filed 2022-08-08 | -$55.90M derived: sum of 3 quarters · filed 2023-02-27 | -$54.30M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$800.00K 10-Q · filed 2022-05-09 | $16.60M derived: sum of 2 quarters · filed 2023-02-27 | $18.20M derived: sum of 3 quarters · filed 2023-02-27 | $11.60M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $19.00M derived: sum of 2 quarters · filed 2023-02-27 | $12.40M derived: sum of 3 quarters · filed 2023-02-27 | $14.00M 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.60M 10-Q · filed 2021-11-08 | -$5.00M derived: sum of 2 quarters · filed 2021-11-08 | -$3.40M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$6.60M 10-Q · filed 2021-08-09 | -$5.00M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $1.60M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $24.80M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $3.80M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |